Trailing twelve months where a flow is involved, latest reported balance where it is not.
Dermatologic is 63% of revenue.
Year to Dec 31, 2025 · $344.2M
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$377.13MQ3 2026+5.6%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
-$12.08MQ3 2026+26.9%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
-$23.01MQ3 2026-18.5%-6.1% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-6.1%Q3 2026-12.3%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
$3.96MQ3 2026+910.4%
Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.
-$0.76Q3 2026-16.9%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
30.07MQ3 2026+1.3%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
32.4xQ1 2025-74.6%
32.4x today · median 127.8x and range 32.4x–452.3x across the points shown, Q1 2020 to Q1 2025 The break in the line covers 7 periods with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
Everything above comes from Castle Biosciences, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 4.54x around Dec 31, 2019 and 2.19x around Dec 31, 2020. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Profit Before Tax, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Dividends paid, Share Repurchases, Change in Payables and Accruals, Change in Other Operating Capital, and Change in Working Capital. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
CSTL · Nasdaq · Healthcare · Diagnostics and Research
$33.78-2.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $385M to $395M for Fiscal year 2026 — up 13.3% on a year earlier, slower than the 23.9% just reported